61324-40-1Relevant articles and documents
Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer
Beetham, Henry,Bougen-Zhukov, Nicola,Cameron, Scott A.,Evans, Gary B.,Fraser, Michael G.,Guilford, Parry J.,Harris, Lawrence D.,Luxenburger, Andreas,Schmidt, Dorian
, p. 18114 - 18142 (2021/12/17)
Diffuse gastric cancer and lobular breast cancer are aggressive malignancies that are frequently associated with inactivating mutations in the tumor suppressor gene CDH1. Synthetic lethal (SL) vulnerabilities arising from CDH1 dysfunction represent attrac
COMPLEMENT MODULATORS AND RELATED METHODS
-
Paragraph 0759, (2020/10/20)
The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.
Naphthyridine compound and pharmaceutical composition as well as applications thereof
-
, (2017/08/02)
The invention relates to the field of biological medicines and discloses a naphthyridine compound and a pharmaceutical composition as well as applications thereof. The naphthyridine compound has a structure shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, a pharmaceutically acceptable salt or a prodrug. The naphthyridine compound disclosed by the invention has an anti-tumor effect which is obviously superior to the anti-tumor effect of the prior art. And moreover, the naphthyridine compound disclosed by the invention can treat diseases mediated by protein kinase.